Nanox.AI vs TeraRecon
One of these finds things nobody asked about and the other is the road they travel on. Nanox.AI, formerly Zebra Medical Vision, mines CT scans taken for unrelated reasons to surface findings such as vertebral compression fractures and coronary calcium, with a deep clearance portfolio built over years and a listed parent whose filings describe the business. TeraRecon is the platform: vendor independent visualisation installed at roughly nineteen hundred sites with a marketplace of partner algorithms, so a health system integrates once rather than per algorithm. The two are complementary in practice. The question opportunistic screening raises, and neither vendor answers, is who pays for the consequences: a finding surfaced from a scan taken for something else creates a follow up obligation, and that cost lands on the health system, not on the algorithm.
- Its strategy is opportunistic population health rather than diagnostic breadth, mining CT scans that were taken for another reason to find findings nobody was looking for.
- A deep clearance portfolio built over years across several anatomical findings, which is the harder path than a single authorisation.
- As the subsidiary of a listed parent, its business is described in filed disclosures, which is a level of accountability private competitors do not carry.
- The installed visualisation base across roughly nineteen hundred sites is the distribution asset, so partner algorithms reach clinicians through infrastructure that already exists.
- Vendor independence from scanners and archives is a genuine architectural position rather than a marketing claim, and it is the reason a mixed estate can standardise on it.
- It holds an independent certification in its own name and has third party recognition behind the platform.
Side by Side
| Axis | N Nanox.AI |
T TeraRecon |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Radiology & Imaging AI page.
Opportunistic screening carries a consequence that neither vendor addresses and buyers rarely price: findings surfaced from a scan taken for another reason generate a duty to act, follow up imaging, patient notification and an incidental finding pathway, and the cost of that pathway falls on the health system rather than the vendor.
Nanox publishes no health privacy commitment, no data governance framework and no subgroup analysis, which is a notable gap for a product designed to run across whole populations. TeraRecon routes model transparency to its partners with no published requirement on them. Neither publishes pricing.